- Home
- JACS vs FHTX Comparison
JACS vs FHTX Comparison
Compare JACS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JACS
- FHTX
- Stock Information
- Founded
- JACS 2024
- FHTX 2015
- Country
- JACS United States
- FHTX United States
- Employees
- JACS N/A
- FHTX N/A
- Industry
- JACS
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- JACS
- FHTX Health Care
- Exchange
- JACS NYSE
- FHTX Nasdaq
- Market Cap
- JACS 303.6M
- FHTX 271.5M
- IPO Year
- JACS 2024
- FHTX 2020
- Fundamental
- Price
- JACS $10.33
- FHTX $5.40
- Analyst Decision
- JACS
- FHTX Strong Buy
- Analyst Count
- JACS 0
- FHTX 8
- Target Price
- JACS N/A
- FHTX $12.63
- AVG Volume (30 Days)
- JACS 73.5K
- FHTX 144.3K
- Earning Date
- JACS 01-01-0001
- FHTX 08-07-2025
- Dividend Yield
- JACS N/A
- FHTX N/A
- EPS Growth
- JACS N/A
- FHTX N/A
- EPS
- JACS N/A
- FHTX N/A
- Revenue
- JACS N/A
- FHTX $23,504,000.00
- Revenue This Year
- JACS N/A
- FHTX $44.01
- Revenue Next Year
- JACS N/A
- FHTX $9.45
- P/E Ratio
- JACS $267.37
- FHTX N/A
- Revenue Growth
- JACS N/A
- FHTX N/A
- 52 Week Low
- JACS $9.94
- FHTX $2.95
- 52 Week High
- JACS $10.41
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- JACS N/A
- FHTX 64.55
- Support Level
- JACS N/A
- FHTX $4.78
- Resistance Level
- JACS N/A
- FHTX $5.52
- Average True Range (ATR)
- JACS 0.00
- FHTX 0.32
- MACD
- JACS 0.00
- FHTX 0.05
- Stochastic Oscillator
- JACS 0.00
- FHTX 86.67
About JACS JACKSON ACQUISITION COMPANY II
Jackson Acquisition Co II is a newly incorporated blank check company.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.